Affinity Asset Advisors LLC has recently announced that it has increased stake in LianBio (NASDAQ:LIAN) by 18.18%. After grabbing 0.65 million shares, the institutional investor is now in possession of 100000.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.60% having worth around $1.2 million.
LianBio (LIAN) concluded trading on 03/15/23 at a closing price of $1.66, with 3.07 million shares of worth about $5.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.91% during that period and on Wednesday the price saw a loss of about -2.63%. Currently the company’s common shares owned by public are about 108.35M shares, out of which, 44.45M shares are available for trading.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the LIAN stock and their offered price forecasts bring an average price target of $7.98. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $15.00 and could fall to a lowest price of $2.92. The stock’s current price level is 79.2% above of average price target set by the analysts, while a rise to estimated low would result in gain of 43.15% for the stock. However, touching the estimated high of $15.00 would mean a gain of 88.93% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 1,238,491 shares in 5 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
T Rowe Price Health Sciences Fund, BlackRock Health Sciences Trust I, and BlackRock Global Funds – World He are the top 3 mutual funds which are holding stakes in LianBio T Rowe Price Health Sciences Fund is currently holding 2.12 million shares of worth totaling $3.91 million. The company recently came buying 2.12 million shares which brought its stake up to 1.95% of the company’s outstanding shares. BlackRock Global Funds – World He, after buying 0.41 million shares, have now control over 0.38% of the stake in the company. It holds 0.0 shares of worth $0.75 million.
LianBio (NASDAQ: LIAN) started trading at $1.70, below -$0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 1.7500, or with a loss of -2.63%. Stock saw a price change of -9.02% in past 5 days and over the past one month there was a price change of -23.97%. Year-to-date (YTD), LIAN shares are showing a performance of 1.52% which decreased to -44.31% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.07 but also hit the highest price of $6.24 during that period. The average intraday trading volume for LianBio shares is 210.92K. The stock is currently trading -12.76% below its 20-day simple moving average (SMA20), while that difference is down -22.71% for SMA50 and it goes to -20.89% lower than SMA200.
Affinity Asset Advisors LLC acquired 0.65 million shares of LianBio having value of about $1.2 million. Data submitted at the U.S SEC by Affinity Asset Advisors LLC revealed that the firm now holds 100000.0 shares in the company valued at close to $166000.0, or have control over 18.18% stake in the company. LianBio (NASDAQ: LIAN) currently have 108.35M outstanding shares and institutions hold larger chunk of about 78.10% of that. Holding of mutual funds in the company is about 53.12% while other institutional holders and individual stake holders have control over 65.09% and 3.41% of the stake respectively.
The stock has a current market capitalization of $191.79M. It has posted earnings per share of -$1.05 in the same period. It has Quick Ratio of 14.70 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LIAN, volatility over the week remained 14.01% while standing at 10.91% over the month.
Analysts are in expectations that LianBio (LIAN) stock would likely to be making an EPS of -$0.27 in the current quarter, while forecast for next quarter EPS is -$0.3 and it is -$1.33 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.44 which is -$0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.28 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -40.60% while it is estimated to decrease by -6.40% in next year.
Analysts at 4 brokerage firms have issued recommendations for the LianBio (LIAN)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 4 Wall Street analysts, 2 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
